Quick Answer
Summit Therapeutics Inc. reported Total Assets of $751.18 million for the year ending 2025.
- Summit Therapeutics Inc. showed an increase of +72.5% in Total Assets from 2024 to 2025.
- This data is from Summit Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $56.87 million | Q1 2021: $140.79 million | Q2 2021: $145.52 million | Q3 2021: $128.67 million | Q1 2022: $116.47 million | Q2 2022: $95.72 million | Q3 2022: $155.33 million | Q1 2023: $254.90 million | Q2 2023: $237.37 million | Q3 2023: $218.48 million | Q1 2024: $176.78 million | Q2 2024: $341.86 million | Q3 2024: $502.85 million | Q1 2025: $383.82 million | Q2 2025: $324.04 million | Q3 2025: $261.73 million.
- Over the full 10 years of available data (2017 to 2025), Summit Therapeutics Inc.'s Total Assets has grown by 1,898.5%.
- Historical annual values: Fiscal year 2025: $751.18 million | Fiscal year 2024: $435.56 million | Fiscal year 2023: $202.95 million | Fiscal year 2022: $664.17 million | Fiscal year 2021: $113.37 million | Fiscal year 2020: $102.50 million | Fiscal year 2019: $96.25 million | Fiscal year 2019: $60.64 million | Fiscal year 2018: $55.17 million | Fiscal year 2017: $37.59 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: